Christopher K.

Assistant Principal Scientist; Cell and Gene Therapy; Merck & Co., Inc.
Summary
Christopher Kloss is a renowned scientist specializing in the development of cutting-edge immunotherapies for cancer.
With a strong academic background, he holds a Doctor of Philosophy (Ph.D.) in Biochemistry, Cell, and Molecular Biology from Weill Cornell Graduate School of Medical Sciences, and a Bachelor's Degree in Biochemistry and Molecular Biology from Michigan State University.
Christopher has an impressive professional journey, serving as an Assistant Principal Scientist at Merck, and playing pivotal roles at prestigious organizations such as The Janssen Pharmaceutical Companies of Johnson & Johnson, University of Pennsylvania, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, National Institutes of Health, and Michigan State University.
His expertise spans over 17 years in academic biotechnology research, with significant contributions in the field of CAR T cell therapy. Notably, he was among the initial employees at The Janssen Pharmaceutical Companies of Johnson & Johnson's CAR T cell exploratory biology group.
Christopher's research includes groundbreaking work on various CAR T cell technologies, such as dual-CAR T cells and iPSC derived CAR T cells, as evidenced in publications like Nature Biotechnology.
During his 4-year post-doc tenure with Dr. Carl June at UPENN, Christopher established a clinical trial focusing on the blockade of TGFb in anti-PSMA CAR T cells, a milestone highlighted in Molecular Therapy in July 2018.
His extensive experience and contributions in the field have solidified his reputation as a leading figure in the development of future immunotherapies for cancer.